Molecular genetics analysis of hereditary breast and ovarian cancer patients in India
Tóm tắt
Hereditary cancers account for 5–10% of cancers. In this study BRCA1, BRCA2 and CHEK2*(1100delC) were analyzed for mutations in 91 HBOC/HBC/HOC families and early onset breast and early onset ovarian cancer cases. PCR-DHPLC was used for mutation screening followed by DNA sequencing for identification and confirmation of mutations. Kaplan-Meier survival probabilities were computed for five-year survival data on Breast and Ovarian cancer cases separately, and differences were tested using the Log-rank test. Fifteen (16%) pathogenic mutations (12 in BRCA1 and 3 in BRCA2), of which six were novel BRCA1 mutations were identified. None of the cases showed CHEK2*1100delC mutation. Many reported polymorphisms in the exonic and intronic regions of BRCA1 and BRCA2 were also seen. The mutation status and the polymorphisms were analyzed for association with the clinico-pathological features like age, stage, grade, histology, disease status, survival (overall and disease free) and with prognostic molecular markers (ER, PR, c-erbB2 and p53). The stage of the disease at diagnosis was the only statistically significant (p < 0.0035) prognostic parameter. The mutation frequency and the polymorphisms were similar to reports on other ethnic populations. The lack of association between the clinico-pathological variables, mutation status and the disease status is likely to be due to the small numbers.
Tài liệu tham khảo
Shanta V, Swaminathan R: Cancer incidence and mortality in Chennai, India 2003–2005. National Cancer registry program, Cancer Institute (WIA), Chennai 2008.
Sue Moss: Screening for breast cancer in India – is it an appropriate strategy? J Natl Cancer Inst 2008, 100(18):1290–1300. 10.1093/jnci/djn292
Miki Y, Swensen J, Donna Shattuck-Eidens, Futreal PA, Harshman K, Tavtigian S, Qingyun Liu, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 . Science 1994, 266: 66–71. 10.1126/science.7545954
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2 . Nature 1995, 378: 789–92. 10.1038/378789a0
Heijboer HM, Ouweland Ans, Klijn J, Wasielewski M, Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, Veghel-Plandsoen M, Elstrodt F, Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton DF, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Gareth Evans D, Houlston R, Murday V, Narod S, Peretz T, Julian P, Phelan C, Zhang HX, Szebo C, Derilee P, Goldgar D, Futreal PA, Nathanson KL, Weber BL, Rahman N, Stratton MR: Low-penetrance susceptibility to breast cancer due to CHEK2 *1100delC in non-carriers of BRCA1 or BRCA2 mutations: The CHEK2 breast cancer consortium. Nat Genet 2002, 31: 55–59. 10.1038/ng879
Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72: 1117–30. 10.1086/375033
Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE: Risks of cancer in BRCA1 -mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994, 343: 692–695. 10.1016/S0140-6736(94)91578-4
Robson ME: Clinical Considerations in the Management of Individuals at Risk for Hereditary Breast and Ovarian Cancer. Cancer Control 2002, 9: 457–465.
Marsh DJ, Zori RT: Genetic insights into familial cancers-update and recent discoveries. Cancer Letters 2002, 181: 125–164.
Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, SEARCH collaborators, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, Fletcher O, Johnson N, Seal S, Stratton MR, Rahman N, Chenevix-Trench G, Bojesen SE, Nordestgaard BG, Axelsson CK, Garcia-Closas M, Brinton L, Chanock S, Lissowska J, Peplonska B, Nevanlinna H, Fagerholm R, Eerola H, Kang D, Yoo KY, Noh DY, Ahn SH, Hunter DJ, Hankinson SE, Cox DG, Hall P, Wedren S, Liu J, Low YL, Bogdanova N, Schürmann P, Dörk T, Tollenaar RA, Jacobi CE, Devilee P, Klijn JG, Sigurdson AJ, Doody MM, Alexander BH, Zhang J, Cox A, Brock IW, MacPherson G, Reed MW, Couch FJ, Goode EL, Olson JE, Meijers-Heijboer H, Ouweland A, Uitterlinden A, Rivadeneira F, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Hopper JL, McCredie M, Southey M, Giles GG, Schroen C, Justenhoven C, Brauch H, Hamann U, Ko YD, Spurdle AB, Beesley J, Chen X, kConFab AOCS Management Group, Mannermaa A, Kosma VM, Kataja V, Hartikainen J, Day NE, Cox DR, Ponder BA: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447: 1087–1093. 10.1038/nature05887
Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Easton DF: Multifactorial analysis of differences between sporadic breast cancer and cancers involving BRCA1 and BRCA2 mutation. J Natl Cancer Inst 1998, 80: 1138–1145. 10.1093/jnci/90.15.1138
Berns EM, Van Staveren IL, Verhoog L, Van De Ouweland AM, Gelder MM, Meijers-Heijboer H, Portengen H, Foekens JA, Dorssers LC, Klijn JG: Molecular profiles of BRCA1 - mutated and matched sporadic breast tumors; relation with clinico-pathological features. British J Cancer 2001, 85: 538–545. 10.1054/bjoc.2001.1937
Lakhani SR: The pathology of familial breast cancer: morphological aspects. Breast Cancer Res 1999, 1: 31–35. 10.1186/bcr10
Bell DW, Erban J, Sgroi DC, Haber DA: Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2 . Cancer Res 2002, 62: 2741–2743.
Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H: A Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005, 7: R93-R100. 10.1186/bcr953
De Carvalho M, Jenkins J, Nehrebecky M, Lahl L: The Role of Estrogens in BRCA1/2 Mutation Carriers. Cancer Nurs 2003, 26: 421–430.
Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, Berchuck A, Muto MG, Garber JE, Weber BL, Lynch HT, Boyd J: Clinical And Pathological Features Of Ovarian Cancer In Women With Germ-Line Mutations Of Brca1 . N Engl J Med 1996, 335: 1413–1416. 10.1056/NEJM199611073351901
Rajkumar T, Soumittra N, Nirmala KN, Swaminathan R, Sridevi V, Shanta V: BRCA1, BRCA2 And CHEK2 (1100 Del C) Germline Mutations In Hereditary Breast And Ovarian Cancer Families In South India. APJCP 2003, 4: 203–208.
FASTA/Hydropathy/Secondary-Structure/Seg[http://fasta.bioch.virginia.edu/fasta_www/chofas.htm]
Schwede T, Kopp J, Guex N, Peitsch MC: SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Research 2003, 31: 3381–3385. 10.1093/nar/gkg520
Guex N, Peitsch MC: SWISS-MODEL and the Swiss-PdbViewer An environment for comparative protein modelling. Electrophoresis 1997, 18: 2714–2723. 10.1002/elps.1150181505
Peitsch MC: Protein modeling by E-mail Bio/Technology. 1995, 13: 658–660.
Thorpe SM, Rose C: Estrogen and progesterone receptor determinations in breast cancer technology and biology. Cancer Surv 1986, 5: 505–525.
Lee A, Park WC, Yim HW, Lee MA, Park G, Lee KY: Expression of c-ErbB2, Cyclin D1 and ER and their clinical implications in Invasive ductal carcinoma of breast. Jpn J Clin Oncol 2007, 37(9):708–714. 10.1093/jjco/hym082
Gullick WJ: Expression of c-ErbB2 protooncogene protein in human breast cancer. Recent results. Cancer Res 1989, 113: 51–56.
Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LR, Anne-Lise Børresen-Dale: Influence of Tp53 gene alterations and c-erbB2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001, 61: 2501–2512.
Wagner TM, Hirtenlehner K, Shen P, Moeslinger R, Muhr D, Fleischmann E, Concin H, Doeller W, Haid A, Lang AH, Mayer P, Petru E, Ropp E, Langbauer G, Kubista E, Scheiner O, Underhill P, Mountain J, Stierer M, Zielinski C, Oefner P: Global sequence diversity of BRCA2 : analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet 1999, 8: 413–23. 10.1093/hmg/8.3.413
Wagner TM, Möslinger RA, Muhr D, Langbauer G, Hirtenlehner K, Concin H, Doeller W, Haid A, Lang AH, Mayer P, Ropp E, Kubista E, Amirimani B, Helbich T, Becherer A, Scheiner O, Breiteneder H, Borg A, Devilee P, Oefner P, Zielinski C: BRCA1 – related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. Int J Cancer 1998, 77: 354–360. 10.1002/(SICI)1097-0215(19980729)77:3<354::AID-IJC8>3.0.CO;2-N
Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA: Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian Cancer. Am. J. Hum 2001, 68: 700–710. 10.1086/318787
Palmieri G, Palomba G, Cossu A, Pisano M, Dedola MF, Sarobba MG, Farris A, Olmeo N, Contu A, Pasca A, Satta MP, Persico I, Carboni AA, Cossu-Rocca P, Contini M, Mangion J, Stratton MR, Tanda F: BRCA1 and BRCA2 Germline mutations in Sardinian breast cancer families and their implications for genetic counseling. Ann Oncol 2002, 13: 1899–1907. 10.1093/annonc/mdf326
Thirthagiri E, Lee SY, Kang P, Lee DS, Toh GT, Selamat S, Yoon SY, Taib NA, Thong MK, Yip CH, Teo SH: Evaluation of BRCA1 and BRCA2 mutation and risk prediction models in Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res 2008, 10: R59. 10.1186/bcr2118
Saxena S, Chakraborty A, Kaushal M, Kotwal S, Bhatanager D, Mohil RS, Chintamani C, Aggarwal AK, Sharma VK, Sharma PC, Lenoir G, Goldgar DE, Szabo CI: Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. BMC Medical Genetics 2006, 7: 1471–2350. 10.1186/1471-2350-7-75
Kumar BV, Lakhotia S, Ankathil R, Madhavan J, Jayaprakash PG, Nair MK, Somasundaram K: Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families. Cancer Biol Ther 2002, 1: 18–21.
Saxena S, Szabo CI, Chopin S, Barjhoux L, Sinilnikova O, Lenoir G, Goldgar DE, Bhatanager D: BRCA1 and BRCA2 in Indian breast cancer patients. Hum Mutat 2002, 20: 473–474. 10.1002/humu.9082
Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, Kant R, Gupta V, Shukla NK, Deo SS, Das BC: Novel germline mutations in breast cancer susceptibility genes BRCA 1, BRCA 2 and p53 gene in breast cancer patients from India. Breast Cancer Res Treat 2004, 88: 177–86. 10.1007/s10549-004-0593-8
Valarmathi MT, Sawhney M, Deo SS, Shukla NK, Das SN: Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families. Hum Mutat 2004, 23: 205. 10.1002/humu.9213
Zelada-Hedman M, Wasteson Arver B, Claro A, Chen J, Werelius B, Kok H, Sandelin K, Håkansson S, Andersen TI, Borg A, Børresen Dale AL, Lindblom A: A screening for BRCA1 mutations in breast and breast-ovarian cancer families from Stockholm region. Cancer Res 1997, 37: 2474–2477.
Meindl A: German consortium for hereditary breast and ovarian cancer: Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002, 97: 472–480. 10.1002/ijc.1626
Ikeda N, Miyoshi Y, Yoneda K, Shiba E, Sekihara Y, Kinoshita M, Noguchi S: Fequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families. Int J Cancer 2001, 91: 83–88. 10.1002/1097-0215(20010101)91:1<83::AID-IJC1013>3.0.CO;2-5
Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalance of BRCA1 and BRCA2 gene Mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999, 91: 943–949. 10.1093/jnci/91.11.943
Gajalakshmi P, Natarajan TG, Rani DS, Thangaraj K: A novel BRCA1 mutation in an Indian family with hereditary breast/ovarian cancer. Breast Cancer Res Treat 2006.
Ho GH, Phang BH, Ng IS, Law HY, Soo KC, Ng EH: Novel germline BRCA 1 mutations detected in women in Singapore who developed breast carcinoma before the age of 36 years. Cancer 2000, 89: 811–816. 10.1002/1097-0142(20000815)89:4<811::AID-CNCR13>3.0.CO;2-R
Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, King MC: Conformation of BRCA 1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994, 8: 399–404. 10.1038/ng1294-399
Nathanson KL, Weber BL: "Other" breast caner susceptibility genes searching for more holy grail. Hum Mol Genet 2001, 10: 715–720. 10.1093/hmg/10.7.715
Novak DJ, Chen LQ, Ghadirian P, Hamel N, Zhang P, Rossiny V, Cardinal G, Robidoux A, Tonin PN, Rousseau F, Narod SA, Foulkes WD: Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian Women. BMC Cancer 2008, 8: 239. 10.1186/1471-2407-8-239
Verhoog LC, Brekelmans CT, Seynaeve C, Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, Ouweland A, Devilee P, Meijers-Heijboer EJ, Klijn JG: Survival and tumor characteristics of breast cancer patients with germline mutations of BRCA1 . Lancet 1998, 351: 316–321. 10.1016/S0140-6736(97)07065-7
Johannsson OT, Ranstam J, Borg A, Olsson H: Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Swden. J Clin Oncol 1998, 16: 397–404.
Lee JS, Wacholder S, Struewing JP, McAdams M, Pee D, Brody LC, Tucker MA, Hartge P: Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 1999, 91: 259–263. 10.1093/jnci/91.3.259
Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K: BRCA -aasociated breast cancer in young women. J Clin Oncol 1998, 16: 1642–1649.